Abstract | PURPOSE:
Adrenocortical carcinoma (ACC) is a rare but aggressive endocrine tumor with limited treatment options. Preclinical studies confirmed overexpression of the chemokine receptor 4 (CXCR4) in this cancer type. This study aimed to analyze the role of CXCR4 imaging using Ga- pentixafor for ACC staging and selection of patients for CXCR4-directed endoradiotherapy. METHODS: Thirty patients with histologically proven advanced, metastasized ACC underwent F-FDG PET/CT and Ga- pentixafor PET/CT within a time interval of 3 ± 4 days to evaluate suitability for CXCR4-directed endoradiotherapy. Scans were analyzed retrospectively for visual extent of ACC and SUVmax/mean of the tumor lesions. Ga- pentixafor PET was compared with F-FDG PET, the reference imaging standard. All patients were rated for suitability of CXCR4-directed endoradiotherapy considering patient's history, previous treatment, and CXCR4 expression of FDG-positive lesions compared with background activity within the same organ. RESULTS: All patients had lesions that were positive for both F-FDG and Ga- pentixafor PET and were rated as positive for disease. In 2 patients (7%), Ga- pentixafor PET identified more lesions compared with F-FDG PET. In 5 patients (17%) and 10 patients (33%), complementary and comparable information, respectively, was provided by dual-tracer imaging. In 13 patients (43%), more tumor lesions were identified by F-FDG PET compared with Ga- pentixafor PET. The F-FDG uptake of the malignant lesions was significantly higher (P < 0.01) than the SUVmax/mean for Ga- pentixafor. Overall, 70% of the patients were rated as suitable or potentially suitable for CXCR4-directed treatment. CONCLUSIONS: Ga- pentixafor allows in vivo imaging of CXCR4 expression in patients with advanced ACC and may serve as companion diagnostic tool in selecting patients for potential CXCR4-directed endoradiotherapy. Seventy percent of the patients with advanced, metastasized ACC may be suitable for a CXCR4-directed treatment after failure of standard treatment options.
|
Authors | Christina Bluemel, Stefanie Hahner, Britta Heinze, Martin Fassnacht, Matthias Kroiss, Thorsten A Bley, Hans-Juergen Wester, Saskia Kropf, Constantin Lapa, Andreas Schirbel, Andreas K Buck, Ken Herrmann |
Journal | Clinical nuclear medicine
(Clin Nucl Med)
Vol. 42
Issue 1
Pg. e29-e34
(Jan 2017)
ISSN: 1536-0229 [Electronic] United States |
PMID | 27819856
(Publication Type: Journal Article)
|
Chemical References |
- 177Lu-pentixather
- 68Ga-pentixafor
- 90Y-pentixather
- CXCR4 protein, human
- Coordination Complexes
- Gallium Radioisotopes
- Peptides
- Peptides, Cyclic
- Radioisotopes
- Receptors, CXCR4
- Yttrium Radioisotopes
- Lutetium
|
Topics |
- Adrenal Cortex Neoplasms
(diagnostic imaging, metabolism, radiotherapy)
- Adrenocortical Carcinoma
(diagnostic imaging, metabolism, radiotherapy)
- Adult
- Aged
- Coordination Complexes
- Female
- Gallium Radioisotopes
- Humans
- Lutetium
(therapeutic use)
- Male
- Middle Aged
- Patient Selection
- Peptides
(therapeutic use)
- Peptides, Cyclic
- Positron Emission Tomography Computed Tomography
- Radioisotopes
(therapeutic use)
- Radionuclide Imaging
- Radiotherapy
- Receptors, CXCR4
(metabolism)
- Yttrium Radioisotopes
(therapeutic use)
|